RM-102

N/A

Report date: 2026/05/12 09:09:41

Base Information

Drug NameRM-102
Drug Alias NameVEGFA CasRm gene therapy (Reforgene Medicine/Sun Yat-Sen university)RM-102
ClassificationCell and gene therapy > Gene therapy > Gene editing > RNA editingCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector
Mechanisms of ActionVascular endothelial growth factor inhibitors
TargetsVascular endothelial growth factor
Therapy Area/IndicationsDiabetic macular oedemaMacular Degeneration
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesSun Yat-Sen University
China Registration ClassN/A

Develop Information

Active CompaniesGuangzhou Reforgene Medicine Co LtdSun Yat-Sen University
Inactive CompaniesN/A
Active IndicationsDiabetic macular oedemaMacular Degeneration
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A